Free tool
FAERS Monitor: Actimmune
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103836 or its brand name (Actimmune, Interferon Gamma-1b). Reports on generic versions are filed under their own applications.
Reports
1,409
Serious
918
65% of reports
Hospitalization
548
Death reported
204
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia193
- off label use178
- pneumonia102
- influenza like illness92
- fatigue68
- death63
- headache61
- chills55
- malaise51
- pain49
- nausea48
- dyspnoea47
- infection41
- vomiting40
- hospitalisation37
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 113 |
| 2005 | 82 |
| 2006 | 110 |
| 2007 | 62 |
| 2008 | 19 |
| 2009 | 9 |
| 2010 | 11 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 8 |
| 2014 | 79 |
| 2015 | 238 |
| 2016 | 215 |
| 2017 | 64 |
| 2018 | 46 |
| 2019 | 98 |
| 2020 | 62 |
| 2021 | 25 |
| 2022 | 40 |
| 2023 | 31 |
| 2024 | 42 |
| 2025 | 22 |
| 2026 | 26 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,750 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| influenza like illnessSignal | 92 | 16.7 | 13.7 | 1,346 |
| pyrexiaSignal | 193 | 8.3 | 7.3 | 1,258 |
| chillsSignal | 55 | 7.0 | 5.4 | 279 |
| pneumoniaSignal | 102 | 4.7 | 3.9 | 298 |
| infectionSignal | 41 | 4.2 | 3.1 | 99 |
| hospitalisationSignal | 37 | 3.6 | 2.6 | 67 |
| off label useSignal | 178 | 3.0 | 2.6 | 251 |
| malaise | 51 | 1.7 | 1.3 | 16 |
| headache | 61 | 1.5 | 1.1 | 8 |
| fatigue | 68 | 1.3 | 1.0 | 5 |
| vomiting | 40 | 1.3 | 0.9 | 2 |
| dyspnoea | 47 | 1.2 | 0.9 | 2 |
| pain | 49 | 1.2 | 0.9 | 1 |
| death | 63 | 1.1 | 0.9 | 0 |
| nausea | 48 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.